Search results
Showing 1486 to 1500 of 9024 results
NICE is unable to make a recommendation on sarilumab (Kevzara) for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1104
Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal) (TA1105)
NICE is unable to make a recommendation on clascoterone (Winlevi) for treating acne vulgaris in people 12 years and over. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1105
NICE is unable to make a recommendation on zanubrutinib (Brukinsa) with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma in adults after 2 or more treatments. This is because BeiGene has requested a delay to the evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA978
Evidence-based recommendations on caplacizumab (Cablivi) with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura in adults, and in young people aged 12 years and over who weigh at least 40 kg.
Evidence-based recommendations on garadacimab (Andembry) for preventing recurrent attacks of hereditary angioedema in people 12 years and over.
NICE is unable to make a recommendation on mirabegron (Betmiga) for treating neurogenic detrusor activity in people 3 to 17 years. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1100
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)
Evidence-based recommendations on sunitinib (Sutent) for untreated advanced or metastatic renal cell carcinoma in adults.
Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)
Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours in adults.
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.
Pemetrexed for the treatment of malignant pleural mesothelioma (TA135)
Evidence-based recommendations on pemetrexed for treating malignant pleural mesothelioma in adults.
Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for relapsed or refractory follicular lymphoma in adults.
Delgocitinib for treating moderate to severe chronic hand eczema (TA1107)
Evidence-based recommendations on delgocitinib (Anzupgo) for treating moderate to severe chronic hand eczema in adults when topical corticosteroids have not worked or are not suitable.
Evidence-based recommendations on atogepant (Aquipta) for preventing migraine in adults.
Iptacopan for treating complement 3 glomerulopathy (terminated appraisal) (TA1102)
NICE is unable to make a recommendation on iptacopan (Fabhalta) for treating complement 3 glomerulopathy in adults. This is because the company has withdrawn from the appraisal.
Show all sections
Sections for TA1102